G
Gordon H. Guyatt
Researcher at McMaster University
Publications - 1749
Citations - 262329
Gordon H. Guyatt is an academic researcher from McMaster University. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 231, co-authored 1620 publications receiving 228631 citations. Previous affiliations of Gordon H. Guyatt include Memorial Sloan Kettering Cancer Center & Cayetano Heredia University.
Papers
More filters
Journal ArticleDOI
Cisapride improves gastric emptying in mechanically ventilated, critically ill patients. A randomized, double-blind trial.
TL;DR: It is concluded that cisapride enhances gastric emptying in critically ill patients and studies to examine the effect of cisap Ride on tolerance to enteral nutrition, infectious morbidity, and other clinically important outcomes are warranted.
Journal ArticleDOI
A Controlled Trial of Ambroxol in Chronic Bronchitis
TL;DR: There was no advantage to taking ambroxol in patients with chronic bronchitis and difficulty clearing secretions, according to a double-blind randomized controlled trial.
Journal ArticleDOI
Minimal important differences for improvement in shoulder condition patient-reported outcomes: a systematic review to inform a BMJ Rapid Recommendation
Qiukui Hao,Tahira Devji,Dena Zeraatkar,Yuting Wang,Anila Qasim,Reed A C Siemieniuk,Per Olav Vandvik,Tuomas Lähdeoja,Alonso Carrasco-Labra,Thomas Agoritsas,Gordon H. Guyatt +10 more
TL;DR: A review provides anchor-based minimal important differences estimates, as well as a rating of their credibility, for PROMs for patients with shoulder conditions, and identified MIDs of high credibility for pain and function outcomes and of low credibility for HRQoL.
Journal ArticleDOI
The history and development of N-of-1 trials:
TL;DR: The understanding of bias suggests that informal ‘trials of therapy’ – comparisons of patients’ condition before and after treatment – do not provide a trustworthy basis for inferring treatment effects, and more sophisticated comparisons are usually needed.
Journal ArticleDOI
Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline.
Ton Kuijpers,Frederick A. Spencer,Reed A C Siemieniuk,Reed A C Siemieniuk,Per Olav Vandvik,Per Olav Vandvik,Catherine M Otto,Lyubov Lytvyn,Hassan Mir,Albert Y. Jin,Veena Manja,Ganesan Karthikeyan,Elke Hoendermis,Janet Martin,Sebastian Carballo,Martin O'Donnell,Trond Vartdal,Christine Baxter,Bray Patrick-Lake,Joanie Scott,Thomas Agoritsas,Thomas Agoritsas,Gordon H. Guyatt +22 more
TL;DR: The linked systematic review finds that PFO closure prevents recurrent stroke relative to antiplatelet therapy, but possibly not relative to anticoagulants, and is associated with procedural complications and persistent atrial fibrillation.